Former Celera CEO and Quest Diagnostics SVP brings track record of building and guiding successful life sciences companies
BILLERICA, Mass. — July 16, 2014 — RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced the appointment of Kathy Ordoñez to its Board of Directors.
Kathy Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. As Senior Vice President at Quest Diagnostics, Ms. Ordonez was initially responsible for leading the company’s R&D effort and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011. Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading producer of genetic testing products for HIV resistance, cystic fibrosis and high complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann La-Roche, overseeing the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer, and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic and forensic fields.
“RainDance has achieved meaningful breakthroughs in the sensitivity and precision of genetic analysis to drive our understanding of cancer, virology, and inherited conditions. The company has multiple products in the market, an established and growing customer base, and a strong development pipeline including non-invasive Fluid Biopsy™ assays,” said Ms. Ordoñez. “I look forward to joining an experienced board and leadership team and contributing to RainDance as the company moves to its next stage of development.”
“Kathy Ordoñez is highly regarded and respected in the life science research and diagnostics industry,” said Michael Hunkapiller, Ph.D., a Board Director at RainDance Technologies. “We believe Kathy’s relationship with the team, creative mindset, and deep industry experience will help RainDance continue its success.”
Complex Genetics Made Simple
RainDance Technologies enables ground-breaking research with an innovative product portfolio to study cell-free and cell-based biomarkers for hereditary risk predisposition, initial detection, pathology and residual disease. The company’s products include:
- RainDrop® System: Ultra-sensitive digital PCR system for research of early detection and monitoring biomarkers for cancers, viruses, pathogens, and immune disorders.
- ThunderBolts™ Cancer Panel: Comprehensive Next-Generation Sequencing (NGS) panel enabling highly sensitive, rapid, low input and primary tumor profiling research in fresh biopsy, plasma and FFPE samples.
- ThunderStorm® System: High-throughput, fully automated NGS content enrichment solution enabling researchers to generate what we believe to be the best-in-class data on large-scale disease panels, while delivering affordable workflow for high-volume studies.